RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cellectar Biosciences Stock

Cellectar Biosciences Stocks 2024

Cellectar Biosciences Stocks

12.22 M

Ticker

CLRB

ISIN

US15117F5008

WKN

A2NB71

In 2024, Cellectar Biosciences had 12.22 M outstanding stocks, a 0% change from the 12.22 M stocks in the previous year.

The Cellectar Biosciences Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e12.22
2028e12.22
2027e12.22
2026e12.22
2025e12.22
2024e12.22
202312.22
20227.06
20215.55
20201.98
20190.77
20180.3
20170.14
20160.05
20150.01
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-

Cellectar Biosciences shares outstanding

The number of shares was Cellectar Biosciences in 2023 — This indicates how many shares 12.222 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cellectar Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cellectar Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cellectar Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cellectar Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cellectar Biosciences Aktienanalyse

What does Cellectar Biosciences do?

Cellectar Biosciences is a biotechnology company specializing in the development of innovative cancer therapies. It was founded in 2003 and is headquartered in Madison, Wisconsin, USA. The company's mission is to revolutionize cancer treatment by developing therapies with high efficacy. Cellectar Biosciences focuses on research and development in the areas of preclinical development, clinical trials, and product registration. It has expanded its business to include radiation therapy and imaging diagnostics. The company is divided into different divisions for effective work and specialization. It has partnerships with leading players in the biotechnology industry. Overall, Cellectar Biosciences has built an impressive portfolio of products and services to meet the needs of patients and healthcare providers and will continue to play a significant role in the biotechnology industry in the future. Cellectar Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Cellectar Biosciences's Shares Outstanding

Cellectar Biosciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Cellectar Biosciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Cellectar Biosciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Cellectar Biosciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Cellectar Biosciences stock

How many stocks are there of Cellectar Biosciences?

The current number of stocks of Cellectar Biosciences is 12.22 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Cellectar Biosciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Cellectar Biosciences evolved in recent years?

The number of shares of Cellectar Biosciences has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Cellectar Biosciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Cellectar Biosciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Cellectar Biosciences pay?

Over the past 12 months, Cellectar Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cellectar Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Cellectar Biosciences?

The current dividend yield of Cellectar Biosciences is .

When does Cellectar Biosciences pay dividends?

Cellectar Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cellectar Biosciences?

Cellectar Biosciences paid dividends every year for the past 0 years.

What is the dividend of Cellectar Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cellectar Biosciences located?

Cellectar Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cellectar Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cellectar Biosciences from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Cellectar Biosciences pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Cellectar Biosciences in the year 2023?

In the year 2023, Cellectar Biosciences distributed 0 USD as dividends.

In which currency does Cellectar Biosciences pay out the dividend?

The dividends of Cellectar Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cellectar Biosciences

Our stock analysis for Cellectar Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectar Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.